To evaluate the impact of hemorheological and hemostasiological disorders on the development of cerebrovascular disease in patients with myeloproliferative disorders (MPD) and to assess the clinical effectiveness of angiocorrective treatment with vinpocetine.
Material and methods
The study included 41 patients with chronic cerebrovascular disorders, including 26 patients with ph-negative MPD. Median age of patients with and without MPD was 44.6 and 56.4 years, respectively. All patients underwent magnetic resonance imaging (MRI) of the brain, tests for hemostasis and hemorheology and cuff test to evaluate the endothelial function. All patients were treated with vinpocetine.
All patients had various degrees of chronic cerebrovascular insufficiency, clinically presenting with headache, vestibular disorders, and sensory deficits. Patients with MPD presented with reduced erythrocyte deformability and increased red blood cell aggregates stability. Cuff test revealed decrease in athrombogenic potential of the vessel wall in patients with MPD. Treatment with vinpocetine alleviated headache, vertigo and atactic gait.
Disorders of hemorheology and hemostasis in patients with MPD play a leading role in the development and progression of cerebrovascular pathology.
Cerebrovascular pathology, myeloproliferative disorders, hemorheology and hemostasis, vinpocetine.